NSE filing, NSE: MOL. Summary written from the filing by ALFA Finder's alert engine.
Meghmani Organics Ltd: key numbers
- Share price
- ₹52.67
- Market cap
- ₹1,339 Cr
- Revenue (annual)
- ₹2,174 Cr
- Net profit (annual)
- ₹28.74 Cr
- P/E (TTM)
- 20.9×Sector 34.1×
- Promoter holding
- 48.95%+0.00% QoQ
- FII holding
- 0.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Meghmani Organics Ltd
All →Meghmani Organics Credit Rating
India Ratings assigned Meghmani Organics' bank loan facilities of INR 11,000 million a rating of IND A/Stable/IND A1. The filing encloses the rating letter and a facilities breakup.
Meghmani Organics Board Meeting Date
Meghmani Organics will hold a board meeting on 4 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. The meeting is a future notice, so no results are yet reported.
Meghmani Organics Other Announcement
Meghmani Organics Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026.
Meghmani Organics Acquisition
Meghmani Organics Limited received an NCLT Ahmedabad Bench order sanctioning the Scheme of Amalgamation of its wholly-owned subsidiaries, Kilburn Chemicals Limited and Meghmani Crop Nutrition Limited, with itself.
Meghmani Organics Annual General Meeting
Meghmani Organics Limited held its 7th Annual General Meeting on September 8, 2026. The meeting concluded successfully with all items of business transacted as proposed.
Meghmani Organics Other Announcement
Meghmani Organics Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report details environmental, social, and governance initiatives.
Other regulatory approval announcements
All →Grasim Industries Regulatory Approval
CCI approved subsidiary ABReN's acquisition of 100% of Solenergi Power from Shell Overseas. The approval clears a regulatory condition for the deal announced on 13 July 2026.
Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.